Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Study Description: This is a pilot study for individuals with chronic granulomatous disease (CGD) using an unmanipulated matched unrelated donor (MUD) graft. The conditioning regimen will use alemtuzumab (Campath-1H, Genzyme Corporation) and total body irradiation (TBI) combined with the investigational new drug JSP191. Participants will receive a high-dose donor graft infusion followed by post-transplant cyclophosphamide (Cytoxan, Baxter International, Inc). This study will determine whether replacing busulfan with the new investigational drug, JSP191, within the alemtuzumab/TBI-based conditioning regimen yields engraftment in patients with CGD. Objectives: Primary Objective: \- To measure the engraftment rates using JSP191 in conjunction with a high cell-dose graft. Secondary Objectives: * To assess overall survival. * To evaluate the safety and efficacy of JSP191 in a TBI- and alemtuzumab-based regimen for transplantation of unmanipulated unrelated donor grafts in patients with CGD. * Assessment of graft versus host disease (GvHD). * Evaluate the long-term engraftment of those receiving JSP191. * To assess the level and kinetics of immune reconstitution. * To evaluate the pharmacokinetic (PK) properties of JSP191 in patients with CGD. Exploratory Objectives: * To assess the impact of inflammatory cytokines on engraftment, inflammatory reactions, and graft rejection. * To further elucidate the factors involved in the development of GvHD and graft rejection/failure. Endpoints: Primary Endpoint: \- Reduced incidence of graft failure or rejection (as defined by \>= 20% engraftment by oxidase-positive neutrophils in \>= 85% of participants by Day 100, 1 year, and 2 years after transplant). Myeloid chimerism and/or oxidase positivity of \>= 20% will be considered engrafted. Secondary Endpoints: * Overall survival. * Safety will be evaluated by recording of adverse events (AEs) related to JSP191 rather than to GvHD or engraftment. An increase in incidence of AEs or development of AEs not typically seen in patients receiving a busulfan-based regimen will be attributed to the use of JSP191. * Assessment of rates of GvHD. * Rates of grade 3 and 4 acute GvHD (aGvHD) of \< 20% (see Appendix B on grading). * Development and incidence of aGvHD and chronic GvHD (cGvHD) with a comparison to historical controls and incidence on parallel protocols using busulfan. * Engraftment at \>2 years and up to 5 years post-transplant. * Reconstitution kinetics using absolute neutrophil and absolute lymphocyte recovery kinetics will be compared as well as impact on immunoglobulin (Ig) levels. \- PK will be measured and compared to historical data supplied by Jasper Therapeutics, Inc. and from other patient populations on other studies at the NIH. Exploratory Endpoints: * Evaluation of inflammatory markers as risk factors for engraftment syndrome and/or graft failure. * Obtain samples for cytokine profiles at various timepoints post-transplant to assess the impact on inflammation profiles by JSP191 in the setting of the conditioning regimen.